Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy - PubMed
a day ago
- #non-small cell lung cancer
- #patient-reported outcomes
- #cemiplimab
- Review of patient-reported outcomes (PROs) in EMPOWER-Lung 1 trial comparing cemiplimab monotherapy vs chemotherapy in advanced NSCLC patients with PD-L1 ≥50%.
- Cemiplimab showed significant improvement in Global Health Status/Quality of Life (GHS/QoL) over chemotherapy in overall and subgroup analyses.
- Key subgroups benefiting from cemiplimab included patients with brain metastasis, ECOG PS 1, squamous/nonsquamous histology, and age ≥65.
- Significant delays in time to deterioration in GHS/QoL were noted for PD-L1 ≥90% and age <65 subgroups with cemiplimab.
- Findings support the GHS/QoL benefit of first-line cemiplimab monotherapy in advanced NSCLC with PD-L1 ≥50%.